Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.

NCT04290871 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT04290871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04290871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.
Lead sponsor
Xijing Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
January 16, 2023
Completion date
April 1, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus covid-19 infection variant omicron, sars (severe acute respiratory syndrome)